Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

Koichi Sugimoto1,2
Nobutaka Shimizu1
Takashi Oki2
Kazuhiro Nose2
Tsukasa Nishioka2
Shogo Adomi3
Takayuki Ohzeki3
Atsunobu Esa3
Hirotugu Uemura1
1Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan; 2Department of Urology, Sakai Hospital Kinki University Faculty of Medicine, Sakai, Osaka, Japan; 3Department of Urology, NTT West Osaka Hospital, Osaka, Osaka, Japan

Background: This study was undertaken to investigate the growth rate and clinical outcome of patients with a small renal mass (SRM) after delayed surgery.

Methods: We reviewed the clinical records of 34 patients with SRMs ≤ 4 cm at diagnosis, who underwent delayed surgical intervention during surveillance from January 2000 to December 2011. Radiographic evaluations using computed tomography (CT) scan and magnetic resonance imaging (MRI) were performed at least every 6 months, and the tumor size was determined at least twice.

Results: The mean follow-up time was 26.6 ± 18.6 months and mean tumor doubling time was 23.4 ± 16.0 months. Histopathological analysis revealed that 32 of the 34 patients were malignant in pT1aN0M0. Only one patient showed tumor recurrence, who subsequently died due to tumor progression.

Conclusion: The growth rate of the small renal mass was slow in the majority of our patients. Delayed intervention does not have a detrimental effect on cancer-specific outcomes.

Keywords: renal cell carcinoma, small renal mass, natural history, growth rate, delayed intervention

Background
Renal cell carcinoma (RCC) has been increasingly detected using noninvasive abdominal imaging techniques, such as ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI).1-5

A retrospective review has revealed that most small renal masses (SRMs) show a slow growth rate and low malignant potential.6-8

In this study, the growth rate and natural history of incidentally diagnosed RCC were investigated during prolonged follow-up in 34 patients who decided to postpone surgical treatment.

Methods
Thirty-four patients, each with an incidentally detected SRM ≤ 4 cm, were retrospectively reviewed at three centers from January 2000 to December 2011. All patients were operated on once the tumor growth was noted. They underwent at least two CT scans prior to surgical intervention.

The maximum tumor diameter and tumor volume were calculated at two points, using images yielded by the same diagnostic modality. Tumor volume (V) was calculated using the following equation, assuming the tumor had a spheroidal form:9

\[ V = \frac{4}{3} \times \pi \times a \times b \times \left[ a + b/2 \right] \times 1/8, \]

where a indicates the maximum tumor diameter and b denotes the minimum tumor diameter.
The time to tumor doubling (TTD) was calculated using the following equation,\textsuperscript{10,11} \[ TTD = \frac{(T - T_0)}{\log_2\log V - \log V_0} \] where \( T - T_0 \) indicates the interval between the two time measurements and \( V_0 \) and \( V \) denote the tumor volume at \( T_0 \) and \( T \) respectively.

Clinical and pathological stages were determined using the 2009 American Joint Committee on Cancer/International Union Against Cancer Classification of Malignant Tumors (TNM) guidelines.\textsuperscript{12} Clinical and pathological characteristics that could be associated with tumor growth rates and stages were investigated. After surgery, a follow-up was conducted with the patients every 3–6 months. Patients under hemodialysis (due to end-stage renal disease) were not included in this study as they are at a greater risk of developing RCC than age-matched healthy controls.\textsuperscript{13–15}

Survival curves were estimated using the Kaplan–Meier formulation. Also, data that were statistically significant were compared using the non-parametric Mann–Whitney U test.

### Results

The mean age of the patients was 64.4 years (35–80). There were 26 men and eight women. Twenty-three patients underwent partial nephrectomy. Eleven patients underwent radical nephrectomy. In all patients, the tumors were \( \leq 4 \) cm at diagnosis. Histopathological analysis revealed that 32 of the 34 patients were malignant in pT1aN0M0.

The mean observation period was 26.2 months (6.5–74.8) and the mean initial tumor volume was \( 6.2 \pm 6.5 \) cm\(^3\) (0.14–30.5). The mean preoperative tumor volume was \( 12.9 \pm 11.9 \) cm\(^3\) (0.7–47.4) and the mean TTD for the entire population was 23.4 months (23.0 months in men, 24.5 months in women, showing no significant difference between sexes). The mean growth rate was 3.9 mm/year (Table 1).

The pathological results confirmed the diagnosis of RCC for 32 of the 34 patients. 26 tumors (76.5%) were clear cell carcinomas, five (14.7%) were papillary cell

| Case | Sex | Age (Years) | Preoperative follow up (months) | Initial tumor volume (cm\(^3\)) | Preoperative tumor volume (cm\(^3\)) | TTD (months) | Growth rate (mm/year) |
|------|-----|-------------|---------------------------------|---------------------------------|--------------------------------------|--------------|-----------------------|
| 1    | Male | 61          | 7.5                             | 20.9                            | 36.3                                 | 8.3          | 5.24                  |
| 2    | Female | 75        | 16.4                            | 2.04                            | 3.93                                 | 7.1          | 2.96                  |
| 3    | Male | 73          | 28.5                            | 9.21                            | 12.8                                 | 10.2         | 4.27                  |
| 4    | Male | 78          | 22.8                            | 4.32                            | 8.66                                 | 28.6         | 2.13                  |
| 5    | Female | 71        | 13.7                            | 9.35                            | 16.9                                 | 14.6         | 3.30                  |
| 6    | Male | 75          | 8.6                             | 9.49                            | 25.3                                 | 17.7         | 2.93                  |
| 7    | Female | 70        | 48.3                            | 2.25                            | 4.11                                 | 48.1         | 0.87                  |
| 8    | Male | 60          | 52.8                            | 1.55                            | 5.46                                 | 61.3         | 3.61                  |
| 9    | Female | 80        | 35.7                            | 5.32                            | 6.66                                 | 25.4         | 1.38                  |
| 10   | Male | 76          | 54.2                            | 30.5                            | 44                                   | 62.3         | 1.71                  |
| 11   | Male | 76          | 41.2                            | 0.61                            | 4.9                                  | 22.7         | 4.24                  |
| 12   | Female | 73       | 19.1                            | 11.5                            | 27.1                                 | 58.2         | 1.47                  |
| 13   | Male | 52          | 14.7                            | 9.88                            | 15.6                                 | 27.6         | 17.62                 |
| 14   | Female | 35        | 56.6                            | 11.2                            | 13.4                                 | 18.8         | 1.94                  |
| 15   | Male | 77          | 6.8                             | 0.59                            | 1.1                                  | 5.5          | 2.32                  |
| 16   | Male | 72          | 6.5                             | 0.14                            | 0.7                                  | 31.5         | 2.79                  |
| 17   | Male | 74          | 6.5                             | 0.52                            | 3.58                                 | 24.6         | 2.27                  |
| 18   | Male | 65          | 6.6                             | 11.6                            | 19.2                                 | 9.9          | 5.71                  |
| 19   | Male | 35          | 7.5                             | 2.55                            | 5.08                                 | 7.5          | 3.87                  |
| 20   | Male | 57          | 59.9                            | 1.9                             | 11.7                                 | 22.8         | 5.71                  |
| 21   | Male | 42          | 41.2                            | 13.6                            | 26.6                                 | 42.7         | 2.48                  |
| 22   | Male | 59          | 6.9                             | 8.62                            | 11.5                                 | 16.7         | 2.25                  |
| 23   | Male | 56          | 45.3                            | 8.42                            | 47.4                                 | 18.1         | 10.50                 |
| 24   | Male | 50          | 23.1                            | 1.2                             | 3.45                                 | 15.1         | 2.82                  |
| 25   | Male | 65          | 74.8                            | 1.2                             | 10.6                                 | 23.7         | 0.52                  |
| 26   | Male | 58          | 23.1                            | 1.05                            | 3.23                                 | 14.2         | 2.74                  |
| 27   | Male | 72          | 28.8                            | 5.32                            | 15.9                                 | 18.3         | 6.38                  |
| 28   | Male | 61          | 20.2                            | 1.6                             | 3.94                                 | 15.6         | 3.20                  |
| 29   | Female | 73      | 9.1                             | 2.59                            | 4.32                                 | 12.3         | 4.14                  |
| 30   | Male | 70          | 39.9                            | 0.48                            | 1.78                                 | 21.1         | 1.38                  |
| 31   | Male | 61          | 21.9                            | 2.6                             | 12.8                                 | 9.5          | 12.20                 |
| 32   | Male | 65          | 11.3                            | 8.16                            | 14.4                                 | 13.7         | 5.68                  |
| 33   | Male | 71          | 24.7                            | 9.12                            | 12.8                                 | 49.6         | 1.18                  |
| 34   | Female | 52       | 6.9                             | 2.83                            | 4.32                                 | 11.4         | 0.64                  |

Abbreviation: TTD, time to tumor doubling.

---

Sugimoto et al

Cancer Management and Research 2013:5
Because local recurrence was found 29 months after the operation, radical nephrectomy was performed, but the patient died due to local recurrence at 54.3 months after the initial operation.

There is no significant difference of TTD according to histopathological grade and subtype. But a strong trend was evident with an almost significant \( P = 0.068 \) (Table 3).

### Discussion

A greater number of small, asymptomatic renal tumors are being incidentally detected nowadays. The positive prognosis of incidental RCC is excellent as evidenced by the results of surgery.\(^{16,17}\) Metastasis may occur in 1%–1.4% of patients with small renal cell carcinoma.\(^6,18\)

Active surveillance is most commonly considered in early prostate cancer, however, recent advances regarding

| Case | Histological subtype | Grade | Tumor number | Tumor number | Postoperative follow up (months) | Clinical outcome recurrence (+/-) |
|------|----------------------|-------|--------------|--------------|----------------------------------|----------------------------------|
| 1    | Clear                | 2     | 1            | 25           | –                                |                                  |
| 2    | Clear                | 2     | 1            | 15.2         | –                                |                                  |
| 3    | Papillary            | Unknown | 1         | 12.4         | –                                |                                  |
| 4    | Clear                | Unknown | 1         | 6.3          | –                                |                                  |
| 5    | Clear                | 2     | 1            | 26.1         | –                                |                                  |
| 6    | Papillary            | 3     | 1            | 37           | –                                |                                  |
| 7    | Clear                | 1     | 1            | 33.6         | –                                |                                  |
| 8    | Clear                | 1     | 1            | 35.7         | –                                |                                  |
| 9    | Clear                | 1     | 1            | 32.3         | –                                |                                  |
| 10   | Clear                | 1     | 1            | 33.4         | –                                |                                  |
| 11   | Clear                | 1     | 1            | 28.6         | –                                |                                  |
| 12   | Papillary            | 2     | 1            | 41.8         | –                                |                                  |
| 13   | Clear                | 1     | 1            | 75.7         | –                                |                                  |
| 14   | Clear                | 2     | 1            | 27.6         | –                                |                                  |
| 15   | Clear                | 2     | 1            | 64.7         | –                                |                                  |
| 16   | Clear                | 1     | 1            | 11.8         | Death (LC)                       |                                  |
| 17   | Papillary            | 2     | 1            | 23.8         | –                                |                                  |
| 18   | Clear                | 2     | 1            | 25.1         | –                                |                                  |
| 19   | Clear                | 1     | 1            | 16.9         | –                                |                                  |
| 20   | Papillary            | 3     | 1            | 19.6         | –                                |                                  |
| 21   | Clear                | 2     | 1            | 32           | –                                |                                  |
| 22   | Clear                | 2     | 1            | 30.1         | –                                |                                  |
| 23   | Clear                | 1     | 1            | 30.3         | –                                |                                  |
| 24   | Clear                | 1     | 1            | 45.7         | –                                |                                  |
| 25   | Multilocular clear   | 3     | 1            | 42.3         | –                                |                                  |
| 26   | Oncocytoma           | –     | 1            | –            | –                                |                                  |
| 27   | Clear                | 2     | 1            | 54.3         | Death (RCC)                      |                                  |
| 28   | Clear                | 1     | 1            | 56.5         | Death (PC)                       |                                  |
| 29   | Oncocytoma           | –     | 1            | –            | –                                |                                  |
| 30   | Clear                | 1     | 1            | 80.1         | –                                |                                  |
| 31   | Clear                | 3     | 1            | 81.4         | –                                |                                  |
| 32   | Clear                | 1     | 1            | 14.8         | –                                |                                  |
| 33   | Clear                | 2     | 1            | 122.8        | –                                |                                  |
| 34   | Clear                | 2     | 1            | 88.7         | –                                |                                  |

**Abbreviations:** Clear, clear cell carcinoma; LC, lung cancer; Multilocular clear, multilocular clear cell renal cell carcinoma; Papillary, papillary cell carcinoma; PC, pancreas carcinoma; RCC, renal cell carcinoma.
tumor detection tools such as ultrasound and high speed CT scans have made surveillance of RCC possible.\textsuperscript{18–22} Active surveillance is becoming more common, in particular in elderly patients or patients with comorbidities, who may not be candidates for surgery. This approach is based on a retrospective cohort study of the growth rate and natural history of incidentally detected small renal tumors.\textsuperscript{21–23}

Factors to be taken into account for SRM treatment involve tumor size at the time of diagnosis as well as tumor proliferation rate; 55% to 60% of SRMs are indolent RCC and 20% to 25% are progressive RCC.\textsuperscript{24,25} Considering preoperative progression factors, these models allow quantitative detailing of the risks of recurrence, metastasis and survival. However, these tools have several limitations regarding highly qualified treatment decisions in the management of SRMs.\textsuperscript{23}

In general, size is proportionate to the grade of malignancy.\textsuperscript{26} In which case, when should tumors be treated proactively? How big must they be in diameter? In the case of SRMs smaller than 1.0 cm, 38%–46% are benign. On the other hand, for lesions larger than 7.0 cm, only 6.3%–7.1% are benign.\textsuperscript{27} It has been reported that renal masses $\geq$ 3 cm in diameter have more aggressive potential, resulting in more metastatic cases.\textsuperscript{28,29}

Moreover, the proliferation rate should also be considered. Renal masses < 2.45 cm at diagnosis were shown to have an average growth rate of 0.13 cm/year, while masses $>$ 2.45 cm had an average growth rate of 0.40 cm/year.\textsuperscript{22} Larger tumors and larger tumor volumes at diagnosis and at the conclusion of observation, tended to progress. Significant differences in both the average growth rate (0.80 cm/year versus 0.3 cm/year) and the average volumetric growth rate (27.1 cm$^3$/year versus 6.2 cm$^3$/year) have also been observed.\textsuperscript{30}

Generally, local recurrence rates of RCC reportedly vary from 0% to 7%, and disease-specific survival probabilities range from 89% to 100%.\textsuperscript{31} In our study 34 of 328 patients underwent delayed surgical intervention. In this study, there was no urgency to operate on patients with a TTD of more than 6 months. As a result, one of 34 patients died of local recurrence.

Active surveillance of SRMs offers oncological efficacy equivalent to surgery in the short/intermediate term.\textsuperscript{32} In our study, although the 5-year OSR was rather low at 72.6%, the 5-year CSSR was 87.5%, and the 5-year CRFR was 96.2%; this was probably because surgery was sufficiently delayed considering the past medical history of each surgical case, although the small number of patients might also have influenced the results. It will be necessary to evaluate a large number of such patients to draw conclusions.

As for the treatment of RCC, if imaging findings suggest a typical malignant tumor or enlargement of the tumor is observed in images showing atypical findings, surgical intervention, such as partial nephrectomy to remove the tumor and preserve renal function, should be recommended to every patient, regardless of age. Finally, appropriate treatment should be decided considering age, past medical history and complications.

In conclusion, because short and intermediate term oncological outcomes of active surveillance for SRMs are the same,\textsuperscript{32} active surveillance including delayed intervention surgery for small renal cell carcinoma may be considered a useful strategy by more institutions and become a treatment option in the future. However, surgical intervention should be considered in case of tumor growth to more than 3–4 cm or by more than 4–5 mm/year while on active surveillance.\textsuperscript{29}

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Wunderlich H, Schumann S, Jantitzky V, et al. Increase of renal cell carcinoma incidence in central Europe. *Eur Urol*. 1998;33(6):538–541.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. *JAMA*. 1999;81(17):1628–1631.
3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. *J Urol*. 2002;167(1):57–60.
4. Lightfoot N, Conlon M, Kreiger N, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. *Eur Urol*. 2000;37(5):521–527.
5. Siemer S, Uder M, Humke U, et al. [Value of ultrasound in early diagnosis of renal cell carcinoma]. *Urologe A*. 2000;39(2):149–153. German [with English abstract].
6. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175(2):425–431.

7. Luhezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182(4):1287–1293.

8. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–2852.

9. Ozono S, Miyao N, Igarashi T, et al. Japanese Society of Renal Cancer. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol. 2004;34(2):82–85.

10. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–1294.

11. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology. 2007;242(2):555–562.

12. Sobin LH, Gospodarowicz MK, Wittekind Ch. TMN Classification of malignant tumours, 7th ed. Oxford, UK: Wiley-Blackwell; 2009.

13. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved – editorial. Am J Nephrol. 1998;18(2):89–95.

14. Chokey PL. Acquired cystic kidney disease. Eur Radiol. 2000;10(11):1716–1721.

15. Hora M, Hes O, Reichting T, et al. Tumours in end-stage kidney. Transplantation Proc. 2008;40(10):3354–3358.

16. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162(6):1930–1933.

17. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review. J Urol. 2008;179(4):1227–1233.

18. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5):555–559.

19. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177(3):849–853.

20. Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol. 2010;57(2):223–232.

21. Jewett MA, Mattar K, Basink J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011;60(1):39–44.

22. Mason RJ, Abdo mell M, Trottier G, et al. Growth kinetics of renal masses: analysis of prospective cohort of patients undergoing active surveillance. Eur Urol. 2011;59(5):863–867.

23. Kim SP, Thompson RH. Approach to the small renal mass: to treat or not to treat. Urol Clin North Am. 2012;39(2):171–179.

24. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179(6):2146–2151.

25. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol. 2009;55(2):287–295.

26. Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB. Pathological features of renal neoplasms classified by size and symptomatology. J Urol. 2006;176(4 Pt 1):1317–1320.

27. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–2220.

28. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176(3):896–899.

29. Lane BR, Tobiert CM, Riedinger CB. Growth kinetics and active surveillance for small renal masses. Curr Opin Urol. 2012;22(5):353–359.

30. Smaldone MC, Kutikov A, Eggleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997–1006.

31. Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol. 2004;45(6):692–705.

32. Patel N, Cranston D, Akhtar MZ, et al. Active surveillance of small renal masses offers short-term oncological efficacy to radical and partial nephrectomy. BJU Int. 2012;110(9):1270–1275.